Physician profile
Marc A Nolan
NPI 1144295312
$2,064.86
in general payments reported to CMS, 2019-2025
11 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.70 · 2022: $1,071 · 2023: $68.75 · 2024: $587 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,071.33 | 2022 | |
| Pfizer INC. | $317.49 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $188.06 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.97 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $128.53 | 2024 | Xarelto |
| Lilly USA, LLC | $40.49 | 2024-2025 | Zepbound, Mounjaro |
| Heartflow, INC. | $38.38 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38.33 | 2025 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $24.70 | 2019 | |
| Novo Nordisk INC | $18.37 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $16.21 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.